Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma.
Ricketts, C Morris, M Gentle, D Shuib, S Brown, Michael D Clarke, Noel W Wei, W Nathan, P Latif, F Maher, E
Ricketts, C
Morris, M
Gentle, D
Shuib, S
Brown, Michael D
Clarke, Noel W
Wei, W
Nathan, P
Latif, F
Maher, E
Citations
Altmetric:
Abstract
Despite therapeutic advances in targeted therapy, metastatic renal cell carcinoma (RCC) remains incurable for the vast majority of patients. Key molecular events in the pathogenesis of RCC include inactivation of the VHL tumour suppressor gene (TSG), inactivation of chromosome 3p TSGs implicated in chromatin modification and remodelling and de novo tumour-specific promoter methylation of renal TSGs. In the light of these observations it can be proposed that, as in some haematological malignancies, demethylating agents such as azacitidine might be beneficial for the treatment of advanced RCC.
Affiliation
Description
Date
2013
Publisher
Collections
Keywords
Type
Article
Citation
Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. 2013, 5 (1):16 Clin Epigenetics